Technology
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Videos
    • Research
    • Patent Portfolio
    • Consumer Products
  • Licensing Opportunities
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Legend Removal
    • Governance
  • Education
    • Background
    • Resources
    • General FAQs
  • Events
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2020 Annual General Meeting
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • CSE: LXX
    • Nasdaq: LEXX
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Feb 01, 2021 6:30am EST

Lexaria Provides Guidance on Upcoming R&D

Jan 15, 2021 3:35pm EST

Lexaria Appoints New Board Member

Jan 15, 2021 6:30am EST

Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants

Jan 12, 2021 7:00am EST

Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering

Jan 08, 2021 4:45pm EST

Lexaria Announces Effective Date for Reverse Stock Split

Dec 22, 2020 6:30am EST

Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH

Dec 10, 2020 6:50am EST

Lexaria Closes Sale of Non-Pharmaceutical THC-Related Assets

Dec 07, 2020 6:45am EST

Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor Conferences

Dec 01, 2020 6:30am EST

Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs

Nov 19, 2020 6:30am EST

Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …13
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
medical cannabinoid research Lexaria Bioscience Corp. | Medical Cannabinoid Research | Home Logo

Lexaria Bioscience Corp. (CSE:LXX; NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

  • Home
  • About
  • Technology
  • Licensing Opportunities
  • Investors
  • News
  • Blog
  • Education
  • Events
  • Contact

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright © 2021 All rights reserved. Web Design, Kelowna Photographers, SEO by Hiilite